Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort. (Q34007717)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Bruce P. Hollingsworth

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Philippe Gabriel Steg

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Deepak L. Bhatt

5

object named as

Deepak L Bhatt

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Christopher M Reid

6

object named as

Christopher M Reid

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

REACH Registry Investigators

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Cardiovascular Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

45-52

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21884025%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

An Update on Aspirin in the Primary Prevention of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Atherothrombosis: a major health burden

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

One-year costs in patients with a history of or at risk for atherothrombosis in the United States

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

The economic implications of treating atherothrombotic disease in Australia, from the government perspective

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Australians at risk: management of cardiovascular risk factors in the REACH Registry

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Drug treatment and cost of cardiovascular disease in Australia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

One-year cardiovascular event rates in outpatients with atherothrombosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Health care costs in the last year of life--the Dutch experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Ageing populations: the challenges ahead

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Life expectancy and health care expenditures: a new calculation for Germany using the costs of dying

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Population ageing and health care expenditure: a school of 'red herrings'?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Inhibition of NF-kappa B by sodium salicylate and aspirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Aspirin resistance: more than just a laboratory curiosity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Aspirin resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Variability in response to aspirin: do we understand the clinical relevance?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Narrative review: aspirin resistance and its clinical implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Association of Long-Distance Corridor Walk Performance With Mortality, Cardiovascular Disease, Mobility Limitation, and Disability

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

The REduction of Atherothrombosis for Continued Health (REACH) Registry: An international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5922.2011.00291.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34007717&oldid=2063187271"